The first glycopeptide-intermediate Staphylococcus aureus in Oman  by Elhag, K.M. et al.
Correspondence 173
ACKNOWLEGMENTS
We thank Mrs Arlete Fernandes and Mrs Manuela Vieira for
excellent technical assistance.
M. D. Pinheiro and M. M. Ribeiro
Laborato´rio de Microbiologia e Serologia, Hospital de S. Joa˜o,
Porto, Portugal
Tel: +351 22550 8381
Fax: +351 22550 8381
E-mail: almeidah@med.up.pt
REFERENCES
1. Anderson RM. Tuberculosis: Old problems and new approaches.
Proc Natl Acad Sci USA 1998; 95: 13352–4.
2. Jonas V, Longiaru M. Detection of Mycobacterium tuberculosis by
molecular methods. Clin Lab Med 1997; 17: 119–28.
3. Pfyffer GE, Welscher H-M, Kissling P et al. Comparison of the
Mycobacteria Growth Indicator Tube (MGIT) with radiometric
and solid culture for recovery of acid-fast bacilli. J Clin Microbiol
1997; 35: 364–8.
4. ChewWK, Lasaitis RM, Schio FA, Gilbert GL. Clinical evaluation
of the Mycobacteria Growth Indicator Tube (MGIT) compared
with radiometric (Bactec) and solid media for isolation of myco-
bacteria species. J Med Microbiol 1998; 47: 821–7.
5. Roberts GD, Koneman EW, Kim YK. Mycobacterium. In: Balows
A, Hausler WJ Jr, Herrman KL, Isenberg HD, Shadomy HJ, eds.
Manual of clinical microbiology. Washington: American Society for
Microbiology, 1991: 304–39.
6. Sturm AW, LeRoux L. Evaluation of the BACTECTMMGITTM
960 system for growth and detection of mycobacteria in human
clinical samples. Rev Port Pneumol 1998; IV(3): 346.
7. Saleh AF, Weyer B, Brons U. Comparison of the BAC-
TECTMMGITTM 960 System with the BactecTM 460TB System
and solid media for the detection of mycobacteria from clinical
specimens in a clinical laboratory. Clin Microb Infect 1999; 5(suppl
3): 95.
8. Hanna BH, Ebrahimzadeh A, Elliott LB et al. Multicenter evalu-
ation of the BACTEC MGIT 960 system for recovery of myco-
bacteria. J Clin Microbiol 1999; 37: 748–52.
9. Pinheiro MD. Comparac¸a˜o de dois me´todos culturais no diag-
no´stico laboratorial de Micobacte´rias. Arq Med 1997; 11: 204–6.
10. Cornﬁeld DB, Beavis KG, Greene JA, Bojak M, Bondi J. Myco-
bacterial growth and bacterial contamination in the Mycobacteria
Growth Indicator Tube and Bactec 460 culture systems. J Clin
Microbiol 1997; 34: 2068–71.
The ﬁrst glycopeptide-intermediate Staphylococcus aureus in
Oman
Glycopeptides have become the drugs of choice for the treat-
ment of infections withmultiresistant Gram-positive pathogens.
However, certain staphylococcal strains with low-level resist-
ance to glycopeptides have increasingly been isolated from
clinical specimens [1]. We report the ﬁrst case of infection with
a glycopeptide-intermediate Staphylococcus aureus (GISA) in
Oman.
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A 50-year-old woman known to have diabetes mellitus,
who had chronic renal failure, underwent renal transplant in
October 1998. Seventeen days later, she was admitted to the
Royal Hospital, Muscat, Oman, with wound infection and
rejection. Dialysis was resumed and she was put on immuno-
suppressive drugs and antibiotics. On 9 November, she
developed a catheter-site infection with S. epidermidis and was
treated with 500 mg of vancomycin, given after each dialysis.
Ten days later, she developed a femoral catheter infection with
methicillin-resistant S. aureus (MRSA). The catheter was
removed and she was treated with 500 mg of vancomycin once
a day. Two days later, vancomycin was stopped and she was
started on 200 mg of teicoplanin once a day. On 6 December
1998 and while on teicoplanin she became septic, and blood
cultures yielded MRSA. On 16 December, teicoplanin was
changed to vancomycin. Although vancomycin was maintained
at therapeutic blood levels, blood cultures continued to yield
MRSA. After 58 days on glycopeptide therapy, the patient
showed no clinical improvement and continued to haveMRSA
bacteremia. She died on 19 January 1999.
Blood cultures were performed by Bact/Alert (Organon
Technica, NC, USA). The isolate was identiﬁed as S. aureus by
standard microbiological procedures. It was then tested for
antibiotic sensitivities by Stokes’ comparative disk diffusion
method [2] and was found to be sensitive to vancomycin and
teicoplanin and resistant to methicillin, gentamicin and fucidin.
The minimum inhibitory concentrations (MICs) of van-
comycin and teicoplanin were determined by the E test method
(AB BIODISK, Solna, Sweden) on BHI agar, used according
to the manufacturers’ instructions, and susceptibilities were
determined according to NCCLS breakpoint standards [3]. The
MIC for both vancomycin and teicoplanin was 4mg/L, which
is considered susceptible by NCCLS standards. However, when
tested at the National Reference Center of Staphylococcus,
Lyon, France, the vancomycin MIC was found to be 6mg/L
and that of teicoplanin was 8mg/L. They used the E test on
BHI agar (AB BIODISK), with an inoculum equivalent to 2
McFarland standard, and incubated for 48 h. Based on French
recommendations of the Antibiogram Committee of the
French Society of Microbiology, this strain was therefore
identiﬁed as GISA. We performed a killing curve with a van-
comycin concentration of 4mg/L in brain–heart infusion (BHI)
broth. One BHI broth containing 4mg/L of vancomycin was
inoculated with the isolate and a similar BHI broth was inocu-
lated with S. aureus NCTC 25923. The isolate was also inocu-
lated into an antibiotic-free BHI broth. The broth cultures
were incubated in a shaking water bath at 37 °C. Colony counts
were performed daily for 4 days at dilutions of 10−1–10−3 by
spreading on blood agar plates. The isolate was initially
inhibited, but resumed growth after 72 h of incubation (Figure
1). Vancomycin trough blood levels were assayed twice a week
during therapy by the ﬂuorescence polarization immunoassay
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Figure 1 Killing curve of Staphylococcus aureus isolate in BHI broth
containing 4mg/L of vancomycin: solid line, S. aureus test strain in
BHI broth containing 4mg/L of vancomycin; dotted line, S. aureus
NCTC 25923 in BHI broth containing 4mg/L of vancomycin; dashed
line, S. aureus NCTC 25923 in antibiotic-free BHI broth.
technique using AXSYM (Abbott, IL, USA) and were found
to range between 6 and 7mg/L.
Only a few cases of vancomycin-resistant S. aureus (VRSA)
have so far been reported in the literature; the ﬁrst in Japan in
1997[ 4]; subsequently, reports came from the UK, France and
the USA [5–7]. Our patient was initially infected with MRSA
and received prolonged treatment with vancomycin and teic-
oplanin. Hiramatsu has shown that someMRSA strains generate
VRSA mutants during vancomycin therapy [8], and, according
to Kaatz et al, teicoplanin resistance may result from prolonged
treatment with teicoplanin [9]. As with this patient, dialysis in
renal failure has been associated with VRSA infection [5].
Although the patient received long and adequate glycopeptide
therapy, as conﬁrmed by the vancomycin blood levels, there
was no clinical or microbiological response to the treatment.
We had no access to arbekacin or quinupristin/dalfopristin,
which were reported to be effective in the treatment of such
infections [8]. The isolate appeared to be sensitive, but the
killing curve test showed heterogeneity, suggesting a hetero-
VRSA strain as described by Hiramatsu and Hanaki [1]. The
reference laboratory then identiﬁed the strain as GISA. The
discrepancy between ourMIC results and those of the reference
laboratory and with the clinical course and outcome clearly
demonstrate the difﬁculties in detecting such strains as suggested
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by Hiramatsu and Hanaki [1]. We are not aware of a report
of GISA from any of the Arabian Gulf countries, although
glycopeptides are frequently used. Since GISA strains are not
readily detectable by the routine laboratory tests used by most
laboratories in this area, we wonder whether this case represents
the tip of the iceberg. We therefore suggest that microbiology
laboratories, particularly in this region, should be aware of these
organisms and should have procedures to detect them. Wide
use of glycopeptides should be discouraged, and these drugs
should be used only when indicated. Infection control pro-
cedures to deal with such strains should be strictly followed.
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